What's New
Estradot (estradiol) transdermal patches: reports of quality and efficacy concerns
Medsafe has published a new monitoring communication following reports of quality and efficacy concerns from consumers associated with the use of Estradot (estradiol) patches. These concerns include:
- return of menopausal symptoms
- issues with patch adhesion.
Medsafe's initial investigation has not identified any product quality issues that explain the adhesion or lack of efficacy issues.
News and Events
| Date | Type | Title |
|---|---|---|
| 7/1/2026 | Notices | Notice of Medsafe Office Closure Christmas/New Year 2025/2026 |
| 22/10/2025 | Monitoring Communication |  Estradot (estradiol) transdermal patches: reports of quality and efficacy concerns |
| 7/10/2025 | Consultation | Clozapine: Proposed changes to blood monitoring and prescribing requirements - consultation closing date extended to 15 October 2025 |
| 23/9/2025 | Alert Communication | Topiramate: New measures and advice to prevent exposure during pregnancy |
| 4/9/2025 | Committees | Classification Database was updated on 3 September 2025 |
| 4/9/2025 | Committees | Recent New Zealand Gazette Notices Relating to Classification |
| 4/9/2025 | Publications | Prescriber Update Vol. 46. No. 3 - September 2025 |
